New antiretroviral agents for the treatment of HIV infection
- 1 July 2004
- journal article
- research article
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 6 (4), 333-339
- https://doi.org/10.1007/s11908-004-0056-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1The Journal of Infectious Diseases, 2004
- An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistanceAIDS, 2003
- A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjectsAIDS, 2003
- HIV-1 Resistance Profile of the Novel Nucleoside Reverse Transcriptase Inhibitor β-D-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine (Reverset™)Antiviral Chemistry and Chemotherapy, 2003
- A Humanized, Nondepleting Anti-CD4 Antibody That Blocks Virus Entry Inhibits Virus Replication in Rhesus Monkeys Chronically Infected with Simian Immunodeficiency VirusAIDS Research and Human Retroviruses, 2002
- Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primatesToxicology, 2002
- Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analoguesBioorganic & Medicinal Chemistry Letters, 2001
- Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samplesAIDS, 2000
- S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 1998
- A Humanized Form of a CD4-Specific Monoclonal Antibody Exhibits Decreased Antigenicity and Prolonged Plasma Half-Life in Rhesus Monkeys While Retaining Its Unique Biological and Antiviral PropertiesAIDS Research and Human Retroviruses, 1997